Scholar Rock Holding Corp (SRRK)

$54.56 -0.16 (-0.29%)
Market Cap 6.34B
Revenue (ttm) 0.00
Net Income (ttm) -377.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.77
Volume 391,561
Avg Vol 1,352,394
Day's Range N/A - N/A
Shares Out 121.79M
Stochastic %K 96%
Beta 0.69
Analysts Strong Sell
Price Target $60.38

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that loca...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
Thinkingman91
Thinkingman91 Aug. 18 at 10:38 PM
$SRRK this is my stock with the largest potential. Also one of the few I called wrong it never came back. This will be multiple of 100s
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 10 at 11:01 PM
$SRRK can you say ready….set…GO!
0 · Reply
prismmarketview
prismmarketview Aug. 10 at 6:53 PM
$SRRK Scholar Rock’s apitegromab BLA review is advancing through a second fill-finish facility, with the FDA data package submitted ahead of schedule. Scholar Rock says it has commercial supply ready and continues to target a potential approval decision by September 30. https://prismmarketview.com/scholar-rock-advances-apitegromab-fda-review-for-spinal-muscular-atrophy/
0 · Reply
TwongStocks
TwongStocks Aug. 7 at 8:25 PM
$SRRK Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.businesswire.com/news/home/20260807011647/en/Scholar-Rock-Announces-FDA-Review-of-Apitegromab-Biologics-License-Application-BLA-for-Spinal-Muscular-Atrophy-SMA-to-Progress-with-Second-Fill-Finish-Facility-Approval-Decision-Anticipated-by-September-30-2026-Action-Date • The FDA has classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). • Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA. • FDA review of the apitegromab BLA will progress solely with the second fill-finish facility.
1 · Reply
Tdorsey1776
Tdorsey1776 Aug. 6 at 6:20 PM
$SRRK Was hoping the ATM offering would cause selloff to add more. GLTA
1 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 1:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-scholar-rock-holding-co-stock/ $SRRK Scholar Rock Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 12:53 PM
$SRRK Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.84 up 14.29% YoY
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:13 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:12 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:10 PM
$SRRK
0 · Reply
Latest News on SRRK
Scholar Rock price target raised to $63 from $56 at JPMorgan

2026-08-17T07:59:33.000Z - 2 days ago

Scholar Rock price target raised to $63 from $56 at JPMorgan

Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status

2026-08-17T07:25:35.000Z - 2 days ago

Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2026, 4:15 PM EDT - 4 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 12, 2026, 1:30 PM EDT - 7 days ago

Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Aug 7, 2026, 5:29 PM EDT - 11 days ago

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

2026-08-07T20:30:42.000Z - 11 days ago

Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

NVO

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Aug 7, 2026, 4:20 PM EDT - 11 days ago

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock price target raised to $76 from $70 at BMO Capital

2026-08-07T12:01:51.000Z - 12 days ago

Scholar Rock price target raised to $76 from $70 at BMO Capital

Scholar Rock price target raised to $60 from $58 at Citi

2026-08-07T11:07:02.000Z - 12 days ago

Scholar Rock price target raised to $60 from $58 at Citi

Scholar Rock Holding Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Scholar Rock Holding Earnings Call Transcript: Q2 2026

Scholar Rock Holding Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Scholar Rock Holding Earnings release: Q2 2026

Scholar Rock Holding Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Scholar Rock Holding Quarterly report: Q2 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

Jul 20, 2026, 11:40 AM EDT - 4 weeks ago

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA

2026-07-20T12:10:31.000Z - 4 weeks ago

Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA

NVO

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

SMA

Scholar Rock Holding Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Scholar Rock Holding Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Scholar Rock Holding Transcript: AGM 2026

Jun 4, 2026, 12:00 PM EDT - 2 months ago

Scholar Rock Holding Transcript: AGM 2026

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 2 months ago

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2026

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026, 9:30 AM EDT - 3 months ago

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

May 20, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock Holding Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:00 AM EDT - 3 months ago

Scholar Rock Holding Transcript: Bank of America Global Healthcare Conference 2026

JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’

2026-05-08T13:33:22.000Z - 3 months ago

JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’

Scholar Rock price target raised to $55 from $53 at Barclays

2026-05-08T10:58:07.000Z - 3 months ago

Scholar Rock price target raised to $55 from $53 at Barclays

Scholar Rock price target raised to $65 from $58 at H.C. Wainwright

2026-05-08T10:39:43.000Z - 3 months ago

Scholar Rock price target raised to $65 from $58 at H.C. Wainwright

Scholar Rock Holding Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock Holding Earnings Call Transcript: Q1 2026

Scholar Rock Holding Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock Holding Earnings release: Q1 2026

Scholar Rock Holding Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock Holding Quarterly report: Q1 2026

Scholar Rock Holding Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock Holding Slides: Q1 2026

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Scholar Rock Holding Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Proxy statement: Proxy filing

Scholar Rock Holding Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Proxy statement: Proxy filing

Scholar Rock initiated with a Buy at Canaccord

2026-04-21T09:11:03.000Z - 4 months ago

Scholar Rock initiated with a Buy at Canaccord

Scholar Rock initiated with a Buy at Canaccord

2026-04-20T20:42:45.000Z - 4 months ago

Scholar Rock initiated with a Buy at Canaccord

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Scholar Rock price target raised to $57 from $54 at Jefferies

2026-04-01T16:50:15.000Z - 5 months ago

Scholar Rock price target raised to $57 from $54 at Jefferies

Scholar Rock price target raised to $58 from $51 at BofA

2026-03-31T16:50:34.000Z - 5 months ago

Scholar Rock price target raised to $58 from $51 at BofA

Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright

2026-03-31T15:41:40.000Z - 5 months ago

Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright

Scholar Rock price target raised to $60 from $53 at Raymond James

2026-03-31T15:16:53.000Z - 5 months ago

Scholar Rock price target raised to $60 from $53 at Raymond James

Scholar Rock rises 15.5%

2026-03-31T14:39:48.000Z - 5 months ago

Scholar Rock rises 15.5%

What Sent Scholar Rock Holding Stock (SRRK) Higher Today?

2026-03-31T13:31:12.000Z - 5 months ago

What Sent Scholar Rock Holding Stock (SRRK) Higher Today?

NVO

Scholar Rock Holding Transcript: Status update

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Scholar Rock Holding Transcript: Status update

Scholar Rock Holding Press release: Status update

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Scholar Rock Holding Press release: Status update

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 8:30 AM EDT - 5 months ago

Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference

Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:30 PM EDT - 5 months ago

Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026

Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 5 months ago

Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 3:26 PM EST - 6 months ago

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock Holding Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Earnings Call Transcript: Q4 2025

Scholar Rock Holding Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Annual report: Q4 2025

Scholar Rock Holding Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Earnings release: Q4 2025

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 7:00 AM EST - 6 months ago

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock to Present at Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 6 months ago

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Feb 10, 2026, 8:00 AM EST - 6 months ago

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Scholar Rock Holding Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 7 months ago

Scholar Rock Holding Transcript: 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Holding Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 7 months ago

Scholar Rock Holding Slides: 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Highlights 2026 Strategic Priorities

Jan 12, 2026, 7:00 AM EST - 7 months ago

Scholar Rock Highlights 2026 Strategic Priorities

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 8 months ago

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Holding Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 8:20 AM EST - 9 months ago

Scholar Rock Holding Transcript: Evercore ISI 8th Annual HealthCONx Conference

Scholar Rock Holding Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 1:00 PM EST - 9 months ago

Scholar Rock Holding Transcript: Citi Annual Global Healthcare Conference 2025

Scholar Rock Holding Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 9 months ago

Scholar Rock Holding Transcript: Jefferies London Healthcare Conference 2025

Scholar Rock Holding Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Earnings Call Transcript: Q3 2025

Scholar Rock Holding Quarterly report: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Quarterly report: Q3 2025

Scholar Rock Holding Earnings release: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Earnings release: Q3 2025

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 14, 2025, 7:00 AM EST - 9 months ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Nov 4, 2025, 8:00 AM EST - 10 months ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:12 AM EDT - 11 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Sep 23, 2025, 7:00 AM EDT - 11 months ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Scholar Rock Holding Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q2 2025

Scholar Rock Holding Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Quarterly report: Q2 2025

Scholar Rock Holding Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Earnings release: Q2 2025

Scholar Rock Holding Slides: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Q2 2025

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock Holding Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Corporate Presentation

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 24, 2025, 6:25 PM EDT - 1 year ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock Holding Transcript: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Transcript: Study Update

Scholar Rock Holding Press release: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Press release: Study Update

Scholar Rock Holding Slides: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Study Update

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:33 AM EDT - 1 year ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 1 year ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock Holding Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Scholar Rock Holding Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2025

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

Scholar Rock Holding Earnings Call Transcript: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q1 2025

Scholar Rock Holding Quarterly report: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Quarterly report: Q1 2025

Scholar Rock Holding Earnings release: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Earnings release: Q1 2025

Scholar Rock Holding Slides: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Slides: Q1 2025

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 14, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock Holding Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Apr 28, 2025, 6:50 AM EDT - 1 year ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 25, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Scholar Rock Holding Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 2:30 PM EST - 1 year ago

Scholar Rock Holding Transcript: TD Cowen 45th Annual Healthcare Conference

Scholar Rock Holding Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q4 2024

Scholar Rock Holding Annual report: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Annual report: Q4 2024

Scholar Rock Holding Earnings release: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Earnings release: Q4 2024

Scholar Rock Holding Slides: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Slides: Q4 2024

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 1 year ago

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 21, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:05 AM EST - 1 year ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Jan 29, 2025, 8:00 AM EST - 1 year ago

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 12:45 PM EST - 1 year ago

Scholar Rock Holding Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Scholar Rock Holding Slides: FY 2025

Jan 14, 2025, 12:45 PM EST - 1 year ago

Scholar Rock Holding Slides: FY 2025

Scholar Rock Highlights 2025 Strategic Priorities

Jan 8, 2025, 4:00 PM EST - 1 year ago

Scholar Rock Highlights 2025 Strategic Priorities

Thinkingman91
Thinkingman91 Aug. 18 at 10:38 PM
$SRRK this is my stock with the largest potential. Also one of the few I called wrong it never came back. This will be multiple of 100s
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 10 at 11:01 PM
$SRRK can you say ready….set…GO!
0 · Reply
prismmarketview
prismmarketview Aug. 10 at 6:53 PM
$SRRK Scholar Rock’s apitegromab BLA review is advancing through a second fill-finish facility, with the FDA data package submitted ahead of schedule. Scholar Rock says it has commercial supply ready and continues to target a potential approval decision by September 30. https://prismmarketview.com/scholar-rock-advances-apitegromab-fda-review-for-spinal-muscular-atrophy/
0 · Reply
TwongStocks
TwongStocks Aug. 7 at 8:25 PM
$SRRK Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.businesswire.com/news/home/20260807011647/en/Scholar-Rock-Announces-FDA-Review-of-Apitegromab-Biologics-License-Application-BLA-for-Spinal-Muscular-Atrophy-SMA-to-Progress-with-Second-Fill-Finish-Facility-Approval-Decision-Anticipated-by-September-30-2026-Action-Date • The FDA has classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). • Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA. • FDA review of the apitegromab BLA will progress solely with the second fill-finish facility.
1 · Reply
Tdorsey1776
Tdorsey1776 Aug. 6 at 6:20 PM
$SRRK Was hoping the ATM offering would cause selloff to add more. GLTA
1 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 1:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-scholar-rock-holding-co-stock/ $SRRK Scholar Rock Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 12:53 PM
$SRRK Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.84 up 14.29% YoY
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:13 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:12 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:10 PM
$SRRK
0 · Reply
Tdorsey1776
Tdorsey1776 Aug. 5 at 2:36 PM
$SRRK Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference Business Wire CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (SRRK.NaE) , a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET.
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 23 at 3:46 PM
$SRRK High on the M&A list, the weight loss product line which retains much higher % of lean mass would be gravy
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 22 at 4:53 PM
$SRRK Silly selloff IMO, but I'll use it as an entry point. GLTA
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 22 at 4:52 PM
$SRRK * The FDA is reviewing apitegromab and is expected to decide on Scholar Rock's (SRRK.NaE) application by September 30, 2026. * UBS analyst Michael Yee said the delay was expected because the European filing included only the Indiana facility, but added this was not a risk to the program, citing trial data showing improved motor function in patients treated with the drug.
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 22 at 4:51 PM
$SRRK The European Medicines Agency (EMA) is awaiting the U.S. Food and Drug Administration's classification of a Bloomington, Indiana situated fill-finish facility following an April inspection, Scholar Rock (SRRK.NaE) said. * A favorable FDA reclassification of the facility could clear the way for the EMA's Committee for Medicinal Products for Human Use to issue an opinion on the drug - apitegromab - later this year, said Scholar Rock (SRRK.NaE). * If the facility is not cleared, the company plans to work with European regulators to advance the application using a second fill-finish facility already included in its U.S. regulatory filing. * Scholar Rock (SRRK.NaE) said the second site makes commercial products and is in good standing with U.S. and European regulators. * CEO David Hallal said Scholar Rock (SRRK.NaE) remains confident it can complete the European review process using either manufacturing site.
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 22 at 3:43 PM
$SRRK $LLY Love this combo, too much lean mass is lost on GLP-1s..... SCHOLAR ROCK (SRRK) Last year, the company said its experimental drug, apitegromab, combined with Lilly's Zepbound, helped patients preserve significantly more lean mass in a mid-stage trial. In Scholar Rock's (SRRK) study, patients who received a combination of tirzepatide - the active ingredient in Zepbound - and Scholar's apitegromab lost 3.4 pounds of lean mass after 24 weeks, compared with those on tirzepatide alone, who lost 7.6 pounds of lean mass.
0 · Reply
TwongStocks
TwongStocks Jul. 20 at 12:01 PM
$SRRK Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) https://www.businesswire.com/news/home/20260719465114/en/Scholar-Rock-Provides-Update-on-Timing-of-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Opinion-for-Apitegromab-Marketing-Authorisation-Application-MAA-for-Spinal-Muscular-Atrophy-SMA Should the FDA reclassify Catalent Indiana, a CHMP opinion would be expected later in 2026. In the event that Catalent Indiana is not reclassified, Scholar Rock will work with the EMA to advance the apitegromab MAA with the Company’s second fill-finish facility, which is included in the apitegromab Biologics License Application (BLA) under FDA review in the U.S. with a September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date. The Company will provide an update during its second quarter earnings call on Thursday, August 6, 2026.
1 · Reply
BioTechHealthX
BioTechHealthX Jul. 19 at 2:38 PM
$SRRK Scholar Rock (SRRK) is developing myostatin inhibitors designed to preserve muscle during GLP-1 weight loss. Could this unique strategy unlock a major obesity-market opportunity? https://biotechhealthx.com/biotech-news/is-scholar-rock-srrk-a-promising-biotech-stock-to-invest-in/
0 · Reply
TwongStocks
TwongStocks Jul. 17 at 12:25 PM
$ZVRA $SRRK Some added info regarding the drugs Bloomberg anticipates will be on the CHMP July agenda for opinions: • Icotrokinra, Arimoclomol, Obicetrapib, & Obicetrapib / Ezetimibe, were on the May CHMP Agenda for the Day 180 List of Outstanding Issues (LoOI). Ensitrelvir was on the May agenda for an update on the on-going application (LoOI was adopted in April). https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-18-21-may-2026_en.pdf • Linerixibat was on the June CHMP agenda for an oral explanation (LoOI was adopted in March). https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-june-2026_en.pdf • Apitegromab was on the March agenda for an oral explanation (LoOI was adopted in January) https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-march-2026_en.pdf
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 16 at 5:22 PM
$SRRK We've recently posted analysis that shows SRRK trades at meaningfully higher revenue multiples than peers...and we mean meaningfully higher multiples. Though none of our posts are ever investment advice, if SRRK trades at meaningfully higher multiples than peers, a reasonable conclusion is that it suggests SRRK upside could be limited. Be careful interpreting our SRRK analysis because today an investor purchased 6,000 SRRK $60 calls (600,000 shares), expiring in August & September. We did not look at the trades in detail but directionally this person/group invested almost $1MM in these 600,000 SRRK calls. It's our experience investors with this much money to speculate are much more experienced, savvy & wise than the 3 of us in this investor club. Put simplest this investor may know something we do not. Of course it is illegal for investors to purchase securities with insider knowledge of non-public information. This is not investment advice.
0 · Reply
Tdorsey1776
Tdorsey1776 Jul. 16 at 2:08 PM
$SRRK $LLY SRRK- its experimental drug, apitegromab, combined with Lilly's Zepbound, helped patients preserve significantly more lean mass in a mid-stage trial. In Scholar Rock's (SRRK.NaE) study, patients who received a combination of tirzepatide - the active ingredient in Zepbound - and Scholar's apitegromab lost 3.4 pounds of lean mass after 24 weeks, compared with those on tirzepatide alone, who lost 7.6 pounds of lean mass.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 10 at 4:18 PM
$SRRK nobody is selling...
0 · Reply